Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Penicillin and B-anthracis.

BARNES JM.

J Pathol Bacteriol. 1947 Jan-Apr;59(1-2):113-25. No abstract available.

PMID:
20266354
2.

Discussion.

Glassman HN.

Bacteriol Rev. 1966 Sep;30(3):657-9. No abstract available.

3.

Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis.

Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, Alibek K.

FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):71-4.

4.

Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.

HENDERSON DW, PEACOCK S, BELTON FC.

J Hyg (Lond). 1956 Mar;54(1):28-36. No abstract available.

5.

Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.

Brookmeyer R, Johnson E, Bollinger R.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10129-32. Epub 2003 Jul 30.

6.

Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence.

Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Factor S, Jones J, Ridzon R, Williams I, Rosenstein N; CDC Adverse Events Working Group.

Emerg Infect Dis. 2002 Oct;8(10):1124-32.

7.

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Stamey K, Steward-Clark E, Schmidt DS, Mothershed E, Pruckler J, Schwartz S, Benson RF, Helsel LO, Holder PF, Johnson SE, Kellum M, Messmer T, Thacker WL, Besser L, Plikaytis BD, Taylor TH Jr, Freeman AE, Wallace KJ, Dull P, Sejvar J, Bruce E, Moreno R, Schuchat A, Lingappa JR, Martin SK, Walls J, Bronsdon M, Carlone GM, Bajani-Ari M, Ashford DA, Stephens DS, Perkins BA.

Emerg Infect Dis. 2002 Oct;8(10):1103-10.

8.

Update: Investigation of bioterrorism-related anthrax, 2001.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2001 Nov 16;50(45):1008-10.

9.

Anthrax: clinical features, pathogenesis, and potential biological warfare threat.

Friedlander AM.

Curr Clin Top Infect Dis. 2000;20:335-49. Review. No abstract available.

PMID:
10943532
10.

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.

Friedlander AM, Pittman PR, Parker GW.

JAMA. 1999 Dec 8;282(22):2104-6. No abstract available.

PMID:
10591317
11.

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM.

Vaccine. 1998 Jul;16(11-12):1141-8.

PMID:
9682372
12.

Postexposure prophylaxis against experimental inhalation anthrax.

Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, et al.

J Infect Dis. 1993 May;167(5):1239-43.

PMID:
8486963
13.

Pathology of experimental inhalation anthrax in the rhesus monkey.

Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Friedlander AM.

Lab Invest. 1995 Nov;73(5):691-702.

PMID:
7474943
14.

Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys.

Kelly DJ, Chulay JD, Mikesell P, Friedlander AM.

J Infect Dis. 1992 Nov;166(5):1184-7.

PMID:
1402033

Supplemental Content

Support Center